Loading stock data…
CGTX
$1.28+0.02 (+1.59%)
Market ClosedLast close May 1
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cognition Therapeutics, Inc. in the Healthcare sector is trading at $1.28. The stock is currently 67% below its 52-week high of $3.83, remaining 8.6% below its 200-day moving average. Technical signals show overbought RSI of 72 and bullish MACD crossover, explaining why CGTX maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 72) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.28
Potential Upside
5%
Whystock Fair Value$1.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$115.27M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-68.53%
Volume
Today's trading volume
832,740
Recent News
Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans
Cognition Therapeutics (NASDAQ:CGTX) executives told investors at the Needham conference that the company is preparing to advance its once-daily oral candidate zervimesine into late-stage development, with an initial focus on psychosis symptoms in dementia with Lewy bodies (DLB) while continuing to
Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ...
Despite financial challenges, Cognition Therapeutics Inc (CGTX) advances zervimesine for DLB psychosis, with significant progress in clinical trials and strong cash reserves.
Cognition Therapeutics Q4 Earnings Call Highlights
Cognition Therapeutics (NASDAQ:CGTX) used its fourth-quarter and full-year 2025 earnings call to outline a shift in development priorities for its lead candidate, zervimesine (CT-1812), with management saying it will now focus on pursuing a registration path in dementia with Lewy bodies (DLB) psycho
Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Cognition Therapeutics...
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
Here is how ANI Pharmaceuticals (ANIP) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.